180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Down 21.1% in December

180 Life Sciences Corp. (NASDAQ:ATNF) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 126,900 shares, a drop of 21.1% from the December 15th total of 160,800 shares. Currently, 7.6% of the company’s stock are sold short. Based on an average daily trading volume, of 2,280,000 shares, the days-to-cover ratio is currently 0.1 days.

180 Life Sciences Stock Performance

180 Life Sciences stock traded down $0.08 during midday trading on Thursday, hitting $1.57. 52,503 shares of the company were exchanged, compared to its average volume of 354,542. 180 Life Sciences has a fifty-two week low of $1.16 and a fifty-two week high of $17.75. The company’s fifty day moving average price is $2.18 and its 200-day moving average price is $2.24.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.